Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M. Rossi A, et al. Among authors: parente b. Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Lancet Oncol. 2014. PMID: 25232001 Review.
Personalizing medicine: strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal.
Araújo A, Coelho A, de Mello RA, Azevedo I, Soares M, Queiroga H, Teixeira E, Parente B, Barata F. Araújo A, et al. Among authors: parente b. Rev Port Pneumol. 2012 Sep-Oct;18(5):244-6. doi: 10.1016/j.rppneu.2012.04.011. Epub 2012 Jun 29. Rev Port Pneumol. 2012. PMID: 22748945 Free article. English, Portuguese. No abstract available.
Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Gridelli C, et al. Among authors: parente b. J Thorac Oncol. 2012 Nov;7(11):1713-21. doi: 10.1097/JTO.0b013e318267cf84. J Thorac Oncol. 2012. PMID: 23059776 Free article. Clinical Trial.
Pemetrexed in second line treatment of non-small cell lung cancer - The portuguese experience.
Araújo A, Barata F, Parente B, Rego S, Teixeira E, Melo M, Queiroga H, Cunha J, Duarte J, Coelho A; Pelo Grupode Estudos do Cancro do Pulmão. Araújo A, et al. Among authors: parente b. Rev Port Pneumol. 2008 Jul;14 Suppl 2:S9-S20. doi: 10.1016/S0873-2159(15)30310-X. Rev Port Pneumol. 2008. PMID: 25967568 Free article. English, Portuguese.
MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut.
Barata F, Queiroga H, Teixeira E, Almodovar MT, Parente B, Soares M. Barata F, et al. Among authors: parente b. Rev Port Pneumol (2006). 2016 Sep-Oct;22(5):287-8. doi: 10.1016/j.rppnen.2016.03.009. Epub 2016 May 6. Rev Port Pneumol (2006). 2016. PMID: 27162148 Free article. Clinical Trial. No abstract available.
Cost and Burden of Non-Small Cell Lung Cancer's in Portugal.
Borges M, Gouveia M, Alarcão J, Sousa R, Teixeira E, Barata F, Laranjeira E, Lopes F, Parente B, Pinheiro L, Vaz-Carneiro A, Costa J. Borges M, et al. Among authors: parente b. Value Health. 2014 Nov;17(7):A626. doi: 10.1016/j.jval.2014.08.2228. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202212 Free article. No abstract available.
126 results